Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2014

View Archived Issues

Scientists identify miR-34a as suppressor of osteoclastogenesis and bone resorption

Antiviral agent from N & N Scientific receives FDA orphan drug designation

Bayer HealthCare establishes collaboration with Kyoto University

Alchemia reports phase III trial results for HA-irinotecan in mCRC

Pfizer discontinues agreement to develop Remoxy

Receptos' TOUCHSTONE trial of RPC-1063 for ulcerative colitis meets endpoints

Vaxart eyes clinical trials of Ebola tablet vaccine

Compugen releases validation results on new cancer immunotherapy target candidate

HRA Pharma acquires rights to ovarian cancer immunotherapy from Pantarhei Bioscience

Genetic risk factors for hepatotoxicity from antituberculosis therapy identified

Chugai reports pipeline progress of third quarter 2014

MicroRNAs linked to preneoplastic gastric conditions

Novel carboxamide derivatives patented for HBV infection

CSIR patents novel oxindoles for tuberculosis

Kurume University discloses new cancer antigen peptide vaccines

Novel compounds disclosed by Roche for schizophrenia and other disorders

Takeda Pharmaceutical prepares new CH24H inhibitors

Eisai discloses new PDE9A inhibitors for Alzheimer's disease

Variants in KCNIP4 associated with ACE inhibitor induced cough

Glassia named FDA orphan drug for graft-versus-host disease

Bristol-Myers Squibb enters into agreement to acquire F-star Alpha

FDA grants fast track designation to ARA-290 for small fiber neuropathy

Philogen begins phase II study of F8-IL10

Amgen reviews milestones of third quarter 2014

Researchers present phase II data for mongersen in active Crohn's disease

Xencor regains rights to XmAb-5871

Chembio Diagnostics signs agreements to develop POC diagnostic tests for Ebola, dengue and cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...